Why Novo May Be the Real Winner in Obesity Drug Boom
For decades, Novo Nordisk was known mainly within the medical community as a quiet Danish powerhouse in diabetes care. Fast-forward to today, and its brand names are practically pop culture references. Wegovy and Ozempic have become synonymous with rapid weight loss, with late-night comedians, TikTok influencers, and even Hollywood scripts weaving them into conversation. Yet the company’s stock,
» Read more about: Why Novo May Be the Real Winner in Obesity Drug Boom »
Read More
Could Peloton Stock Deliver a 3-Bagger Comeback?
Remember when Peloton (NASDAQ: PTON) was the crown jewel of lockdown-era stocks? In early 2021, shares soared above $160, but today, it’s trading below $7.
The plunge may be the death knell for most stocks but here’s what might surprise most investors, beneath the wreckage, there are signs of a quiet but serious transformation.
» Read more about: Could Peloton Stock Deliver a 3-Bagger Comeback? »
Read More
Why Roblox Stock Has Doubled & Might Just Be Getting Started
If you blinked, you might have missed it, Roblox (NYSE: RBLX) has turned into one of the hottest stocks of 2025.
Up over 2x year-to-date, the company’s market cap has surged past $80 billion, stunning many who once dismissed the platform as a pandemic fad. But here’s the best part, there’s reason to believe Roblox is only just getting warmed up.
» Read more about: Why Roblox Stock Has Doubled & Might Just Be Getting Started »
Read More
Where Will Robinhood Stock By 2030?
Robinhood doesn’t need to become the next Apple to reward shareholders. It just needs to keep doing what it’s doing, only better, smarter, and at a larger scale. Fortunately, that seems to be exactly the path it’s on.
Let’s uncover why Robinhood might be one of the more under-appreciated fintech stories unfolding right now.
» Read more about: Where Will Robinhood Stock By 2030? »
Read More
Buffett Would Love This Moat, Freeport’s Hidden Growth Engine
In the short run, tariff headlines can turn Mr. Market into a nervous wreck. In the long run, owners do fine by owning scarce, low-cost assets run by rational people. Freeport-McMoRan fits that bill.
U.S. copper prices sold off after Washington excluded refined copper from its new 50% tariffs and instead targeted semi-finished products like wire,
» Read more about: Buffett Would Love This Moat, Freeport’s Hidden Growth Engine »
Read MoreThe Burst
Pfizer’s Big Win Means What For Investors?
Pfizer just pulled off a big deal as it relates to the pharmaceutical landscape in the U.S. On Tuesday, the CEO announced a wide-ranging agreement with the Trump administration that will lower drug prices for many Americans.
At the center of this deal is a new government-backed portal called “TrumpRx”, a website designed to help patients access discounted prescription drugs by connecting them directly to manufacturers’ platforms.
» Read more about: Pfizer’s Big Win Means What For Investors? »
Read MoreThe Ivy
Is Micron’s AI Gold Rush a Perfect Storm?
Micron Technology soared by more than 42.98% over the last 30 days, a jaw-dropping rally even by tech’s feverish standards. The reason? Artificial intelligence and specifically, the voracious appetite for memory chips powering the world’s new AI data centers.
But beneath the surface of the AI euphoria, do the fundamentals justify the soaring share price?
» Read more about: Is Micron’s AI Gold Rush a Perfect Storm? »
Read MoreThe Daily
Is Matthews Asia Innovators Investor (MATFX) a Strong Mutual Fund Pick Right Now?
If you have been looking for Sector – Tech funds, it would not be wise to start your search with Matthews Asia Innovators Investor (MATFX). MATFX carries a Zacks Mutual Fund Rank of 5 (Strong Sell), which is based on various forecasting factors like size, cost, and past performance.
MATFX is part of the Sector –